Skip to content
Open access

Short-term morphological and functional outcomes of intravitreal faricimab for chorioretinal disorders: a real-world study in a Chinese population

Aug 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 29 references
Medicine

TL;DR

In this short-term real-world study comprising three exploratory disease-specific cohorts of Chinese patients, faricimab was associated with favorable anatomical and functional outcomes and was well tolerated, with the most pronounced benefit in treatment-naïve nAMD eyes.

Abstract

Objective To evaluate the real-world efficacy and safety of the bispecific antibody faricimab in Chinese patients with neocascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vascular occlusion (RVO-ME). Methods This retrospective, single-center study included 63 patients (74 eyes: 47 nAMD, 19 DME, 8 RVO-ME); no subjects dropped out. Of the 74 eyes, 37.8% were treatment-naïve and 62.2% were treatment-experienced. All eyes received intravitreal faricimab 6 mg in a three-dose loading regimen followed by pro re nata (PRN) retreatment. Best-corrected visual acuity (BCVA, ETDRS letters) and central macular thickness (CMT) were assessed at baseline, 1 month, 3 months, and final follow-up (mean follow-up, 23.9 ± 12.3 weeks). Subgroup analyses by prior treatment status were performed. Results Faricimab was associated with anatomical and functional improvements. In nAMD, treatment-naïve patients (n = 17) showed significant BCVA improvement (62.52 ± 5.80 to 71.05 ± 15.68 letters, P = 0.037) and CMT reduction (477.86 ± 189.45 to 324.19 ± 137.62 μm, P = 0.001) at final follow-up. Previously-treated nAMD patients (n = 30) showed only a transient CMT reduction at 3 months (P = 0.022) without sustained visual improvement. After the first injection, intraretinal fluid resolved in 90% of nAMD eyes that had IRF at baseline. After three loading doses, complete resolution of subretinal fluid and pigment epithelial detachment (PED) occurred in 66.7% and 31.3% of eyes, respectively. In DME, treatment-naïve patients (n = 9) achieved early BCVA improvement at 1 month (P = 0.0273) and sustained benefit at final follow-up (P = 0.0180), whereas previously-treated patients (n = 10) showed delayed improvement at 3 months in both BCVA and CMT (P = 0.0117 and 0.0195). In RVO-ME, BCVA improved significantly at 3 months and final follow-up (P = 0.018 and 0.028), whereas CMT showed a nonsignificant decrease. No significant ocular or systemic adverse events were observed. Conclusion In this short-term real-world study comprising three exploratory disease-specific cohorts of Chinese patients, faricimab was associated with favorable anatomical and functional outcomes and was well tolerated, with the most pronounced benefit in treatment-naïve nAMD eyes. Responses in DME and RVO-ME were more variable and appeared to be influenced by prior treatment history; these subgroup analyses were exploratory, and larger prospective studies are warranted.

Read PDF

Similar papers

Open access Sep 2026

One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration.

PURPOSE To assess one-year real-world outcomes of faricimab therapy in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF agents and managed using a treat-and-extend (TAE) regimen. METHODS Patients with treatment-resistant nAMD were switched to faricimab. Functional an...

Sebastian Hoffmann, Constance Liegl, Isabel Stasik et al. · 0 citations
Open access Sep 2026

Early clinical outcomes after switching to faricimab in previously treated diabetic macular edema

To evaluate short-term functional, anatomical, morphologic, and optical coherence tomography angiography (OCTA)-derived outcomes after switching to intravitreal faricimab in previously treated diabetic macular edema (DME) with persistent or recurrent center-involving retinal fluid after conventional anti-vascular e...

Jing Chen, Bin Chen · 0 citations
Open access Aug 2026

Functional and Anatomic Outcomes at 12 Months After Switching to Faricimab in Treatment-Recalcitrant Neovascular Age-Related Macular Degeneration.

Purpose: To evaluate functional and anatomic outcomes over 12 months in patients with recalcitrant neovascular age-related macular degeneration (nAMD) whose treatment was transitioned to faricimab. Methods: This retrospective observational study included 36 patients (41 eyes) with treatment-recalcitrant nAMD previously...

S. Mohammadi, Hayden Sikora, J. Bisen et al. · 0 citations
Open access Oct 2026

Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study

The aim of this work is to evaluate the early real-world effectiveness, anatomical outcomes, and safety of intravitreal aflibercept 8 mg in neovascular aged-related macular degeneration (nAMD) eyes. This retrospective single-center study included consecutive nAMD eyes treated with at least one aflibercept 8-mg injectio...

J. Fricker, L. Séjournet, J. Prange et al. · 0 citations
Open access Sep 2026

Real-world anatomical and functional outcomes following Faricimab therapy in neovascular age-related macular degeneration: a one-year observational study

Introduction This study evaluated 12-month anatomical and functional outcomes of Faricimab in Italian patients with neovascular age-related macular degeneration (nAMD). Methods 30 eyes from 30 participants who completed the 12-month follow-up were retrospectively analyzed at “Luigi Vanvitelli” University Eye Clinic (Na...

Settimio Rossi, C. Gesualdo, M. Trotta et al. · 0 citations
Aug 2026

Real-world outcomes after switching to faricimab in treatment-resistant neovascular AMD: Short-term response and 12-month follow-up.

AimsTo assess the efficacy and safety of faricimab in neovascular age-related macular degeneration (nAMD) resistant to anti-VEGF therapies.MethodsThis retrospective study evaluated nAMD patients with persistent fluid despite anti-VEGF treatments (aflibercept or ranibizumab; mean injection interval of 4.63 ± 0.78 weeks)...

Victoria Marechal, F. Amoroso, Sorana Pacurariu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.